10th CyberKnife System Installed at an HCA Hospital

Centennial Medical Center Brings Benefits of Whole Body Radiosurgery to
Nashville

SUNNYVALE, Calif., June 24 /PRNewswire-FirstCall/ -- Accuray Incorporated
(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today
that the 10th CyberKnife(R) Robotic Radiosurgery System was installed at a
Hospital Corporation of America (HCA) facility. The installation took place at
The Sarah Cannon Cancer Center at Centennial Medical Center in Nashville,
Tenn.

"The Sarah Cannon Cancer Center is proud to continue delivering on its promise
to provide the highest quality, most advanced cancer treatment options in our
region with the addition of the CyberKnife System," said Rocky Billups,
administrator for The Sarah Cannon Cancer Center Network. "With this new
image-guided robotic technology, we are giving new hope to those whose tumors
were previously thought to be inoperable and untreatable."

This installation marks HCA's ninth installation in the United States. HCA's
first international installation took place in London at The Harley Street
Clinic in December 2008.

"Our relationship with HCA has provided an additional avenue for getting
patients throughout the world access to the treatment benefits of
radiosurgery," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The
installation at Centennial Medical Center marks the first CyberKnife System in
Nashville and enables local patients to conveniently receive outpatient
treatment for their cancer right in their backyard."

About The Sarah Cannon Cancer Center Network

The Sarah Cannon Cancer Center Network--accredited by The Cancer Commission of
the American College of Surgeons with commendations for providing superior
cancer care -- is second to none in the Southeast for the diagnosis and
treatment of cancer. With eight affiliated medical facilities, The Sarah
Cannon Cancer Center Network has grown to become the largest community-based,
privately-funded diagnostic and treatment center in the country.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body stabilization
frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global
leader in the field of radiosurgery dedicated to providing an improved quality
of life and a non-surgical treatment option for those diagnosed with cancer.
Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which
extends the benefits of radiosurgery to include extracranial tumors, including
those in the spine, lung, prostate, liver and pancreas. To date, the
CyberKnife System has been used to treat more than 60,000 patients worldwide
and currently more than 164 systems have been installed in leading hospitals
in the Americas, Europe and Asia. For more information, please visit
www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
commercialization of products, clinical studies, and regulatory review and
approval are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements speak only as of the date the statements are made
and are based on information available at the time those statements are made
and/or management's good faith belief as of that time with respect to future
events. You should not put undue reliance on any forward-looking statements.
Important factors that could cause actual performance and results to differ
materially from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our products
with complementary technology; and other risks detailed from time to time
under the heading "Risk Factors" in our report on Form 10-K for the 2008
fiscal year, as updated in our Form 10-Q filed on May 6, 2009 and our other
filings with the Securities and Exchange Commission. The Company's actual
results of operations may differ significantly from those contemplated by such
forward-looking statements as a result of these and other factors. We assume
no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent required by
applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Euan Thomson, Ph.D.
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

SOURCE Accuray

Stephanie Tomei, Senior Manager, Public Relations of Accuray, +1-408-789-4234,
stomei@accuray.com; or Brianne Donahue of Schwartz Communications,
+1-415-817-2545, bdonahue@schwartz-pr.com